生殖线激活PDGFRB变体对受体氨酸激酶抑制剂的可变反应:对治疗的影响
Ileana Cristea1,2,3, Roya Mehrasa2,4, Titas Gladkauskas2,3
1Department of Ophthalmology, Haukeland University Hospital, Bergen, Norway.
激活血小板衍生生长因子受体-β (PDGFRβ) 的生殖系变异会导致各种疾病. 不同的PDGFRβ变异对氨酸激酶抑制剂具有不同的敏感性,有助于个性化治疗决策.
科学领域:
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
背景情况:
- 血小板衍生生长因子受体-β (PDGFRβ) 是一个受体氨酸激酶,对细胞生长和分化至关重要.
- 在PDGFRB的生殖系变异与各种遗传疾病有关,包括婴儿肌纤维素瘤和过早衰老综合征.
- 一些PDGFRβ变异导致构成性激活,驱动异常细胞增殖和瘤发育.
研究的目的:
- 总结PDGFRB中经常出现的激活生殖系变异.
- 评估这些变体对各种类型的氨酸激酶抑制剂 (TKI) 的敏感性.
- 为PDGFRB相关疾病患者提供支持个性化治疗策略的数据.
主要方法:
- 在PDGFRB中报告的激活生殖系变异的文献综述.
- 对不同TKIs的变异敏感性的分析.
- 在体外发现与现有体内数据的相关性.
主要成果:
- 在PDGFRB中确定了复发性激活生殖系变异.
- 证明了PDGFRβ氨基酸替代物对特定TKI的差异敏感性.
- 观察到体外TKI灵敏度与先前体内实验结果之间的相关性.
结论:
- 激活PDGFRβ变体对TKIs表现出不同的反应.
- 这种不同的敏感性可以为PDGFRB相关疾病提供个性化医疗方法.
- 这些发现可以指导医疗保健提供者为患有这些遗传疾病的患者选择最佳治疗方法.
更多相关视频
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Receptor Tyrosine Kinases
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
